AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2112882
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human alpha-interferon (4 million units per day, three times weekly for 16 weeks)
Trial: 369300
Drug: Lithium medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium medication (24 mval/day to 36 mval/day)
Trial: 30428772
Drug: treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment as usual (TaU)
Trial: 18413111
Drug: SADBE sensitization
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SADBE sensitization doses (12.5, 25, 50, or 250 microg)
Trial: 18413111
Drug: Elicitation doses
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elicitation doses (0, 0.2, 2, 20, and 200 microg)
Trial: 14725822
Drug: Trazodone 100
RxNorm normalized name: traZODone 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 100 mg
Trial: 10220927
Drug: Ethanol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.5 or 0.8 g/kg)
Trial: 760861
Drug: Daily chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily chemotherapy with reinforcements every 3 months
Trial: 760861
Drug: Reinforcement therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinforcement therapy only every 6 weeks
Trial: 22214885
Drug: Actions enabling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actions enabling benefit from misfortune (e.g., betting on stock decline)
Trial: 16126118
Drug: Captopril and
RxNorm normalized name: captopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril and 120 mg diltiazem
Trial: 11791949
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (Bupropion SR and Methylphenidate)
Trial: 10408666
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (400 mg/day) for 60 days
Trial: 10408666
Drug: Zinc plus
RxNorm normalized name: Zinc plus Copper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc plus arginine supplementation (4 g/day) for 60 days
Trial: 10408666
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (vaccine only)
Trial: 31439007
Drug: Sensor-equipped insoles
RxNorm normalized name: aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sensor-equipped insoles combined with photo documentation and smartphone application (Smart Prevent Diabetic Feet Application) for daily foot temperature measurements.
Trial: 27937077
Drug: Royal Jelly
RxNorm normalized name: ROYAL JELLY
DrugBank: Royal jelly (DB14250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Royal Jelly (RJ) - 9 capsules (350 mg/capsule) per day for 3 months
Trial: 27937077
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 9 capsules per day for 3 months
Trial: 25275693
Drug: Vaginal insert
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal insert containing 10 mg timed-release dinoprostone (PGE2)
Trial: 19497091
Drug: Acetylcysteine 1200
RxNorm normalized name: acetylcysteine 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine 1200 mg orally twice daily for two doses before and two doses after the procedure
Trial: 15983801
Drug: 100 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ng/ml ketamine
Trial: 15151264
Drug: Intravenous calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous calcitriol pulse doses (2‐8 mcg/3x/week)
Trial: 11488772
Drug: Adrenomedullin (ADM)
RxNorm normalized name: THP-Adm
DrugBank: Adrenomedullin (DB19102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenomedullin (ADM) infusion (1-30 pmol x min(‐1))
Trial: 11488772
Drug: Proadrenomedullin N‐terminal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proadrenomedullin N‐terminal 20 peptide (PAMP) infusion (100-3000 pmol x min(‐1))
Trial: 11488772
Drug: Adrenomedullin (ADM)
RxNorm normalized name: THP-Adm
DrugBank: Adrenomedullin (DB19102)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenomedullin (ADM) co-infused with NEP inhibitor thiorphan (30 nmol x min(‐1))
Trial: 9138439
Drug: Intravenous pentagastrin
RxNorm normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous pentagastrin
Trial: 3046645
Drug: Aspirin (330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (330 mg three times a day) plus dipyridamole (75 mg three times a day) for a mean of 25 months, with warfarin for three months.
Trial: 3046645
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for a mean of 23 months, with warfarin for three months.
Trial: 29805116
Drug: Elobixibat 10
RxNorm normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Elobixibat 10 mg/day for 2 weeks
Trial: 29805116
Drug: Elobixibat (varied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elobixibat (varied doses: 5 mg/day, 10 mg/day, or 15 mg/day) for 52 weeks
Trial: 28277886
Drug: Endometrin® 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrin® 200 mg/day (Group A)
Trial: 28277886
Drug: Endometrin® 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrin® 300 mg/day (Group B)
Trial: 28277886
Drug: Endometrin® 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrin® 200 mg/day (control group)
Trial: 26194656
Drug: Bupivacaine 0.25
RxNorm normalized name: levobupivacaine 0.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25 % (40 ml)
Trial: 26194656
Drug: Levobupivacaine 0.25
RxNorm normalized name: levobupivacaine 0.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.25 % (40 ml)
Trial: 21923426
Drug: Formoterol 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 24 μg
Trial: 10912983
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 400 microg
Trial: 12004271
Drug: Drugs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs with DLHigh
Trial: 12004271
Drug: Drugs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs with DLLow
Trial: 12004271
Drug: Each active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each active drug with DLHigh
Trial: 12004271
Drug: Each active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each active drug with DLLow
Trial: 12004271
Drug: No drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drugs with IQ > median
Trial: 12004271
Drug: One drug
RxNorm normalized name: mometasone Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drug with IQ > median
Trial: 12004271
Drug: Two drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two drugs with IQ > median
Trial: 12004271
Drug: Three drugs
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three drugs with IQ > median
Trial: 12004271
Drug: Four or
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four or five drugs with IQ > median
Trial: 7605186
Drug: Intravenous orphenadrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous orphenadrine citrate (60mg)
Trial: 2189123
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (0, 15, 30, or 60 mg daily for six months)
Trial: 478162
Drug: Domperidone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (20 mg t.d.s before meals)
Trial: 29498351
Drug: High-Ca fat-free
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Ca fat-free milk phase (MD) - approximately 1500 mg of Ca/d
Trial: 29498351
Drug: Low-Ca phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Ca phase (CD) - approximately 800 mg of Ca/d
Trial: 26224203
Drug: CYP2C19 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CYP2C19 inhibitors (felbamate, oxcarbazepine)
Trial: 26224203
Drug: Concomitant use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant use of AEDs that are either CYP450 inhibitors or inducers with clobazam
Trial: 17109385
Drug: IGIV-C (Gamunex,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV-C (Gamunex, 10%) infused at 0.08 mL/kg/min
Trial: 17109385
Drug: IGIV-C (Gamunex,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV-C (Gamunex, 10%) infused at 0.11 mL/kg/min
Trial: 17109385
Drug: IGIV-C (Gamunex,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV-C (Gamunex, 10%) infused at 0.14 mL/kg/min
Trial: 17109385
Drug: IGIV-C (Gamunex,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV-C (Gamunex, 10%) at all infusion rates
Trial: 17109385
Drug: IGIV-C (Gamunex,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGIV-C (Gamunex, 10%) at 0.14 mL/kg/min
Trial: 11862176
Drug: Silon-TSR (Bio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silon-TSR (Bio Med Sciences) followed by Aquaphor ointment
Trial: 2237768
Drug: Sequential gradient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential gradient intermittent pneumatic compression applied for 4 hours each day.
Trial: 2237768
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment with ulcer debridement, cleaning, nonadherent dressing, and graduated compression stockings).
Trial: 31374367
Drug: Comprehensive assessments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive assessments (Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity questionnaire)
Trial: 28957556
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (infliximab or prednisone and SSZ)
Trial: 25692241
Drug: Dinoprostone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone (3 mg)
Trial: 23645763
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control of weekly docetaxel regimen
Trial: 20680427
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) at 24% oxygen at 1.3 ATA for 40 sessions
Trial: 12590402
Drug: Amitriptyline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (75 mg/day)
Trial: 19444001
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Amitriptyline 75 mg/day and Fluvoxamine 100 mg/day)
Trial: 9475648
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (5 mL x kg(‐1) every 30 min)
Trial: 8582538
Drug: Intralipid infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid infusion (10% triglyceride emulsion) at a rate of 0.4 ml/min with heparin (200 U bolus followed by 0.2 U/min per kg body weight) for 24 hours
Trial: 8582538
Drug: Intralipid infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid infusion (10% triglyceride emulsion) for 24 hours
Trial: 8582538
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.9% NaCl infusion)
Trial: 8582538
Drug: Recovery test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery test after discontinuation of Intralipid infusion
Trial: 2215098
Drug: Lidocaine group
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine group (2 mL 4% lidocaine solution injected through the catheter)
Trial: 380941
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate (MPSS), 30 mg/kg
Trial: 380941
Drug: Dexamethasone sodium
RxNorm normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone sodium phosphate (DSP), 6 mg/kg
Trial: 31003229
Drug: OnabotulinumtoxinA (additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA (additional injections into toe muscles: flexor digitorum longus, flexor hallucis longus)
Trial: 26903253
Drug: Integrative Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Group Therapy for SMD, 11-week duration, participants stabilized on psychostimulant medication.
Trial: 26903253
Drug: Community-based psychosocial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based psychosocial treatment, control group.
Trial: 17595241
Drug: 1700 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1700 mg/d metformin treatment for 6 months
Trial: 17595241
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) administered using a traditional incremental-dose protocol for 6 months
Trial: 9764962
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg oral dose of tacrine
Trial: 7942079
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive treatment
Trial: 31593756
Drug: Hypofractionated radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiation therapy (HF) - 64.6 Gy in 19 fractions
Trial: 31593756
Drug: Conventionally fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally fractionated radiation therapy (CF) - 78.0 Gy in 39 fractions
Trial: 29393690
Drug: 600 µg
RxNorm normalized name: P.G. 600 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 µg vaginal misoprostol 6 hours before IUD insertion
Trial: 24622517
Drug: Continue hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continue hormone therapy (HT+)
Trial: 24622517
Drug: Discontinue hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinue hormone therapy (HT-)
Trial: 24622517
Drug: Concurrent progestins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent progestins with either 17βE or CEE
Trial: 23527013
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation 400 IUs daily for 2 months
Trial: 23527013
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation 2000 IUs daily for 2 months
Trial: 23527013
Drug: Baseline vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline vitamin D deficiency (25(OH)D<20 ng/ml)
Trial: 17440528
Drug: Plant sterol-rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol-rich diet (2 g/day sitosterol)
Trial: 17440528
Drug: Plant sterol-rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterol-rich diet (1 g/day sitosterol)
Trial: 10972368
Drug: Nifedipine 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 30 mg (long-acting gastrointestinal-transport-system formulation)
Trial: 10972368
Drug: Co-amilozide (hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amilozide (hydrochlorothiazide 25 mg plus amiloride 2.5 mg)
Trial: 8797136
Drug: Dolasetron mesylate
RxNorm normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dolasetron mesylate (1.2, 1.8, and 2.4 mg/kg i.v.)
Trial: 8797136
Drug: Ondansetron (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (32 mg i.v.)
Trial: 8459374
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of droperidol, hyoscine, and metoclopramide in subtherapeutic doses
Trial: 8459374
Drug: Droperidol (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (1.25 mg) alone
Trial: 3080868
Drug: Intralipid (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid (50 g soya oil emulsified with egg lecithin)
Trial: 3080868
Drug: Lipofundin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipofundin (50 g soya oil emulsified with soya lecithin)
Trial: 26988798
Drug: Arjuna extract
RxNorm normalized name: Terminalia arjuna whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arjuna extract 750 mg twice daily
Trial: 23444397
Drug: ERN/LRPT (extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERN/LRPT (extended release niacin 2 g plus laropiprant 40 mg daily)
Trial: 21253392
Drug: Cholecalciferol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (1000 IU) and calcium citrate (800 mg) daily
Trial: 21253392
Drug: Cholecalciferol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (1000 IU) and calcium citrate (800 mg) daily + sodium fluoride (25 mg bid)
Trial: 21253392
Drug: Cholecalciferol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (1000 IU) and calcium citrate (800 mg) daily + ibandronate (1 mg iv/3‐monthly)
Trial: 10744088
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg alosetron
Trial: 10886042
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg alosetron
Trial: 1397674
Drug: 75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/kg captopril
Trial: 1397674
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day enalapril
Trial: 1397674
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day delapril hydrochloride
Trial: 28614793
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of CBD
Trial: 29635142
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for panic disorder (PD)
Trial: 26714287
Drug: Standard, body-weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard, body-weight-based tacrolimus dosing
Trial: 22572418
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg once weekly)
Trial: 22572418
Drug: Oral penicillin
RxNorm normalized name: penicillin G Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral penicillin (phenoxy methyl penicillin 250 mg twice daily)
Trial: 20840200
Drug: Brief treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief treatment (two-session)
Trial: 20840200
Drug: Extended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended treatment (nine-session)
Trial: 18047921
Drug: telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan 40 mg/day
Trial: 18047921
Drug: valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 80 mg/day
Trial: 16231111
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gel (Chlorhexamed) for 15 minutes (3 x 5 min) every 12 weeks
Trial: 16231111
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish (Fluoridin) applied to all teeth 4 and 8 weeks after CHX treatments
Trial: 8750365
Drug: Ramipril-chlorthalidone combination
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril-chlorthalidone combination treatment (5 mg + 25 mg)
Trial: 8750365
Drug: Chlorthalidone monotherapy
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone monotherapy (25 mg daily)
Trial: 29693757
Drug: Adjunctive probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive probiotics (Lactobacillus rhamnosus strain GG and Bifidobacterium animalis subsp. lactis strain Bb12)
Trial: 29693757
Drug: Adjunctive probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive probiotics
Trial: 17663737
Drug: YM150 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YM150 3 mg